Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lupron Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced May 21, 2026, 11:58 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
Male only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
LMIS 50 mg
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Homewood, Alabama • San Diego, California • Meridian, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced May 21, 2026, 11:58 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
leuprolide acetate
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
New Port Richey, Florida • Lawrenceville, New Jersey • Poughkeepsie, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced May 21, 2026, 11:58 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Precocious Puberty, Central
Interventions
Leuprolide Acetate 45 mg
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
2 Years to 9 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Interventions
everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced May 21, 2026, 11:58 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Prostate Cancer
Interventions
No intervention
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced May 21, 2026, 11:58 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Endometriosis
Interventions
Leuprolide Oral Tablet - 120 mg - QD- Treatment A, Leuprolide Oral Tablet - 80 mg - QD - Treatment B, Leuprolide Oral Tablet - 60 mg - QD - Treatment C, Leuprolide Oral Tablet - 60 mg - BID - Treatment D, Leuprolide Oral Tablet - 40 mg - BID - Treatment E
Drug
Lead sponsor
Enteris BioPharma Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Sarasota, Florida • Columbus, Ohio • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
Interventions
Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Amenorrhea, Premature Ovarian Failure, Ovarian Function Insufficiency
Interventions
Leuprolide Acetate, Questionnaire, Hematopoietic Stem Cell Transplantation
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced May 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Placebo, Eligard 22.5Mg Suspension for Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boca Raton, Florida • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Cancer of Prostate
Interventions
leuprolide acetate
Drug
Lead sponsor
San Bernardino Urological Associates Medical Group Inc
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprolide Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced May 21, 2026, 11:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Leuprolide, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced May 21, 2026, 11:58 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
High-Risk Prostate Cancer
Interventions
Capivasertib, abiraterone acetate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
West Los Angeles, California • The Bronx, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide 7.5 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Puberty, Precocious
Interventions
Lupron (leuprolide acetate)
Drug
Lead sponsor
Abbott
Industry
Eligibility
Up to 10 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced May 21, 2026, 11:58 PM EDT